These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 35702932)

  • 41. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
    Kwok WC; Ho JCM; Tam TCC; Ip MSM; Lam DCL
    Thorac Cancer; 2022 Jul; 13(14):2057-2063. PubMed ID: 35668712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
    Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N
    BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
    Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.
    Zhou Y; Wang B; Qu J; Yu F; Zhao Y; Li S; Zeng Y; Yang X; Chu L; Chu X; Li Y; Zou L; Guo T; Ye L; Liang F; Wang S; Liu Q; Ni J; Zhu Z
    Lung Cancer; 2020 Dec; 150():178-185. PubMed ID: 33186860
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis.
    Vanderpoel J; Emond B; Ghelerter I; Milbers K; Lafeuille MH; Lefebvre P; Ellis LA
    Pharmacoecon Open; 2023 Jul; 7(4):617-626. PubMed ID: 37074589
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations.
    Shah R; Lester JF
    Clin Lung Cancer; 2020 May; 21(3):e216-e228. PubMed ID: 32014348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
    Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y
    Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
    Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
    Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
    Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
    J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903.
    Ito K; Morise M; Wakuda K; Hataji O; Shimokawaji T; Takahashi K; Furuya N; Takeyama Y; Goto Y; Abe T; Kato T; Ozone S; Ikeda S; Kogure Y; Yokoyama T; Kimura M; Yoshioka H; Murotani K; Kondo M; Saka H
    ESMO Open; 2021 Jun; 6(3):100115. PubMed ID: 33984681
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
    Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
    JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
    Miyawaki T; Kenmotsu H; Yabe M; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Deguchi S; Mitsuya K; Naito T; Murakami H; Mori K; Harada H; Hayashi N; Takahashi K; Takahashi T
    Invest New Drugs; 2021 Dec; 39(6):1732-1741. PubMed ID: 34259953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
    Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Tamiya N; Goto Y; Kanda H; Chihara Y; Kunimatsu Y; Katayama Y; Iwasaku M; Tokuda S; Takayama K
    Target Oncol; 2023 Sep; 18(5):657-665. PubMed ID: 37610516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims Databases.
    Soo RA; Seto T; Gray JE; Thiel E; Taylor A; Sawyer W; Karimi P; Marchlewicz E; Brouillette M
    Drugs Real World Outcomes; 2022 Mar; 9(1):31-41. PubMed ID: 34510401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overall Survival with Osimertinib in Untreated,
    Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
    N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
    Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot DM; Tan EH; Tanaka H; Wu YL; Yang JC; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N
    Lung Cancer; 2019 Jun; 132():126-131. PubMed ID: 31097085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.